AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. BIIB
  4. [Form 4] Biogen Inc. Insider Trading Activity

[Form 4] Biogen Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Biogen Inc. (BIIB) has filed a Form 4 indicating that director William A. Hawkins acquired 2,370 shares of the company鈥檚 common stock on 06/17/2025. The transaction is coded 鈥淎鈥� (acquisition) and carries a reported price of $0, suggesting the shares were granted rather than purchased on the open market. Following the transaction, Hawkins鈥� direct beneficial ownership stands at 8,860 shares.

The filing confirms Hawkins鈥� role as a director and notes the document was signed on 06/18/2025 by attorney-in-fact Wendell Taylor. No derivative security activity or additional transactions were reported.

Biogen Inc. (BIIB) ha presentato un Modulo 4 che indica che il direttore William A. Hawkins ha acquisito 2.370 azioni ordinarie della societ脿 il 17/06/2025. L'operazione 猫 classificata come 鈥淎鈥� (acquisizione) e riporta un prezzo di $0, il che suggerisce che le azioni siano state assegnate e non acquistate sul mercato aperto. Dopo questa transazione, la propriet脿 diretta di Hawkins ammonta a 8.860 azioni.

Il documento conferma il ruolo di Hawkins come direttore e specifica che 猫 stato firmato il 18/06/2025 dall鈥檃vvocato delegato Wendell Taylor. Non sono state segnalate attivit脿 su strumenti derivati n茅 altre transazioni.

Biogen Inc. (BIIB) ha presentado un Formulario 4 indicando que el director William A. Hawkins 补诲辩耻颈谤颈贸 2.370 acciones ordinarias de la compa帽铆a el 17/06/2025. La transacci贸n est谩 codificada como 鈥淎鈥� (adquisici贸n) y tiene un precio reportado de $0, lo que sugiere que las acciones fueron otorgadas y no compradas en el mercado abierto. Tras la operaci贸n, la propiedad directa de Hawkins es de 8.860 acciones.

El documento confirma el rol de Hawkins como director y se帽ala que fue firmado el 18/06/2025 por el apoderado Wendell Taylor. No se reportaron actividades con valores derivados ni transacciones adicionales.

Biogen Inc. (BIIB)電� 鞚挫偓 William A. Hawkins臧赌 2025雲� 6鞗� 17鞚�鞐� 須岇偓 氤错喌欤� 2,370欤�毳� 旆摑頄堧嫟瓿� 氇呾嫓頃� Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 瓯半灅電� 鈥淎鈥�(旆摑)搿� 攵勲霅橂┌ 氤搓碃霅� 臧赌瓴╈潃 $0搿�, 鞚措姅 欤检嫕鞚� 鞁滌灔鞐愳劀 甑Г霅� 瓴冹澊 鞎勲媹霛� 攵�鞐悳 瓴冹瀯鞚� 鞁滌偓頃╇媹雼�. 鞚� 瓯半灅 頉� Hawkins鞚� 歆侅爲 氤挫湢 欤检嫕 靾橂姅 8,860欤�鞛呺媹雼�.

頃措嫻 靹滊電� Hawkins臧赌 鞚挫偓鞛勳潉 頇曥澑頃橂┌, 2025雲� 6鞗� 18鞚� 雽�毽澑 Wendell Taylor臧赌 靹滊獏頄堨潓鞚� 氇呾嫓頃╇媹雼�. 韺岇儩 歃濌秾 頇滊彊鞚措倶 於旉岸� 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

Biogen Inc. (BIIB) a d茅pos茅 un formulaire 4 indiquant que le directeur William A. Hawkins a acquis 2 370 actions ordinaires de la soci茅t茅 le 17/06/2025. La transaction est cod茅e 芦 A 禄 (acquisition) et affiche un prix d茅clar茅 de 0 $, ce qui sugg猫re que les actions ont 茅t茅 attribu茅es et non achet茅es sur le march茅 libre. Apr猫s cette op茅ration, la d茅tention directe de Hawkins s鈥櫭﹍猫ve 脿 8 860 actions.

Le document confirme le r么le de Hawkins en tant que directeur et pr茅cise qu鈥檌l a 茅t茅 sign茅 le 18/06/2025 par l鈥檃vocat mandat茅 Wendell Taylor. Aucune activit茅 sur des titres d茅riv茅s ni transaction suppl茅mentaire n鈥檃 茅t茅 signal茅e.

Biogen Inc. (BIIB) hat ein Formular 4 eingereicht, das angibt, dass der Direktor William A. Hawkins am 17.06.2025 2.370 Aktien des Unternehmens erworben hat. Die Transaktion ist mit 鈥濧鈥� (Erwerb) gekennzeichnet und weist einen gemeldeten Preis von 0 $ auf, was darauf hindeutet, dass die Aktien gew盲hrt und nicht am freien Markt gekauft wurden. Nach der Transaktion h盲lt Hawkins direkt 8.860 Aktien.

Die Meldung best盲tigt Hawkins鈥� Rolle als Direktor und weist darauf hin, dass das Dokument am 18.06.2025 vom Bevollm盲chtigten Wendell Taylor unterzeichnet wurde. Es wurden keine Aktivit盲ten mit Derivaten oder weitere Transaktionen gemeldet.

Positive
  • Director William A. Hawkins increased his direct holdings by 2,370 shares, raising total ownership to 8,860 shares.
Negative
  • None.

Insights

TL;DR: Small insider share increase; signal is mildly positive but not materially impactful.

The Form 4 shows director William A. Hawkins adding 2,370 BIIB shares, bringing his direct holdings to 8,860. The $0 price indicates a grant, likely automatic board compensation, which limits predictive value regarding future share performance. Nonetheless, the greater alignment of a board member鈥檚 interests with shareholders is generally viewed constructively. Given the modest size relative to Biogen鈥檚 ~145 million shares outstanding, market impact should be minimal.

TL;DR: Routine equity award increases board alignment; governance status unchanged.

This filing documents a standard equity grant to a non-executive director. Such grants are common practice to align board incentives with long-term shareholder value. There are no red flags: the form is timely, correctly signed, and contains no dispositions. From a governance lens, the transaction is benign and supportive, but not a catalyst for strategic change.

Biogen Inc. (BIIB) ha presentato un Modulo 4 che indica che il direttore William A. Hawkins ha acquisito 2.370 azioni ordinarie della societ脿 il 17/06/2025. L'operazione 猫 classificata come 鈥淎鈥� (acquisizione) e riporta un prezzo di $0, il che suggerisce che le azioni siano state assegnate e non acquistate sul mercato aperto. Dopo questa transazione, la propriet脿 diretta di Hawkins ammonta a 8.860 azioni.

Il documento conferma il ruolo di Hawkins come direttore e specifica che 猫 stato firmato il 18/06/2025 dall鈥檃vvocato delegato Wendell Taylor. Non sono state segnalate attivit脿 su strumenti derivati n茅 altre transazioni.

Biogen Inc. (BIIB) ha presentado un Formulario 4 indicando que el director William A. Hawkins 补诲辩耻颈谤颈贸 2.370 acciones ordinarias de la compa帽铆a el 17/06/2025. La transacci贸n est谩 codificada como 鈥淎鈥� (adquisici贸n) y tiene un precio reportado de $0, lo que sugiere que las acciones fueron otorgadas y no compradas en el mercado abierto. Tras la operaci贸n, la propiedad directa de Hawkins es de 8.860 acciones.

El documento confirma el rol de Hawkins como director y se帽ala que fue firmado el 18/06/2025 por el apoderado Wendell Taylor. No se reportaron actividades con valores derivados ni transacciones adicionales.

Biogen Inc. (BIIB)電� 鞚挫偓 William A. Hawkins臧赌 2025雲� 6鞗� 17鞚�鞐� 須岇偓 氤错喌欤� 2,370欤�毳� 旆摑頄堧嫟瓿� 氇呾嫓頃� Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 瓯半灅電� 鈥淎鈥�(旆摑)搿� 攵勲霅橂┌ 氤搓碃霅� 臧赌瓴╈潃 $0搿�, 鞚措姅 欤检嫕鞚� 鞁滌灔鞐愳劀 甑Г霅� 瓴冹澊 鞎勲媹霛� 攵�鞐悳 瓴冹瀯鞚� 鞁滌偓頃╇媹雼�. 鞚� 瓯半灅 頉� Hawkins鞚� 歆侅爲 氤挫湢 欤检嫕 靾橂姅 8,860欤�鞛呺媹雼�.

頃措嫻 靹滊電� Hawkins臧赌 鞚挫偓鞛勳潉 頇曥澑頃橂┌, 2025雲� 6鞗� 18鞚� 雽�毽澑 Wendell Taylor臧赌 靹滊獏頄堨潓鞚� 氇呾嫓頃╇媹雼�. 韺岇儩 歃濌秾 頇滊彊鞚措倶 於旉岸� 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

Biogen Inc. (BIIB) a d茅pos茅 un formulaire 4 indiquant que le directeur William A. Hawkins a acquis 2 370 actions ordinaires de la soci茅t茅 le 17/06/2025. La transaction est cod茅e 芦 A 禄 (acquisition) et affiche un prix d茅clar茅 de 0 $, ce qui sugg猫re que les actions ont 茅t茅 attribu茅es et non achet茅es sur le march茅 libre. Apr猫s cette op茅ration, la d茅tention directe de Hawkins s鈥櫭﹍猫ve 脿 8 860 actions.

Le document confirme le r么le de Hawkins en tant que directeur et pr茅cise qu鈥檌l a 茅t茅 sign茅 le 18/06/2025 par l鈥檃vocat mandat茅 Wendell Taylor. Aucune activit茅 sur des titres d茅riv茅s ni transaction suppl茅mentaire n鈥檃 茅t茅 signal茅e.

Biogen Inc. (BIIB) hat ein Formular 4 eingereicht, das angibt, dass der Direktor William A. Hawkins am 17.06.2025 2.370 Aktien des Unternehmens erworben hat. Die Transaktion ist mit 鈥濧鈥� (Erwerb) gekennzeichnet und weist einen gemeldeten Preis von 0 $ auf, was darauf hindeutet, dass die Aktien gew盲hrt und nicht am freien Markt gekauft wurden. Nach der Transaktion h盲lt Hawkins direkt 8.860 Aktien.

Die Meldung best盲tigt Hawkins鈥� Rolle als Direktor und weist darauf hin, dass das Dokument am 18.06.2025 vom Bevollm盲chtigten Wendell Taylor unterzeichnet wurde. Es wurden keine Aktivit盲ten mit Derivaten oder weitere Transaktionen gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HAWKINS WILLIAM A
(Last) (First) (Middle)
BIOGEN INC.
225 BINNEY ST.
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/17/2025 A 2,370 A $0 8,860 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Wendell Taylor, Attorney in Fact for William Allen Hawkins III 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many Biogen (BIIB) shares did director William A. Hawkins acquire?

He acquired 2,370 shares of common stock.

What is Hawkins鈥� total Biogen share ownership after the transaction?

After the acquisition, he directly owns 8,860 shares.

What transaction code is listed in the Form 4 for BIIB?

The filing lists transaction code "A", indicating an acquisition.

At what price were the shares reported as acquired?

The reported acquisition price is $0 per share.

When was the Form 4 for William A. Hawkins signed and filed?

It was signed on 06/18/2025 and covers a transaction dated 06/17/2025.
Stock BIIB logo
Biogen Inc

NASDAQ:BIIB

BIIB Rankings

#768 Ranked by Market Cap
N/A Ranked by Dividends

BIIB Latest News

Jul 25, 2025
ZURZUVAE庐 (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
Jul 21, 2025
Biogen to Highlight Scientific Progress Across Alzheimer鈥檚 Disease at the Alzheimer鈥檚 Association International Conference 2025
Jul 21, 2025
Biogen Announces $2 Billion Manufacturing Investment in North Carolina鈥檚 Research Triangle Park in Conjunction with its 30th Anniversary
Jul 10, 2025
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
Jun 30, 2025
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

BIIB Latest SEC Filings

Jul 16, 2025
[Form 4] Biogen Inc. Insider Trading Activity
Jul 8, 2025
[144] Biogen Inc. SEC Filing
Jul 7, 2025
[8-K] Biogen Inc. Reports Material Event
Jun 23, 2025
[8-K] Biogen Inc. Reports Material Event
Jun 18, 2025
[Form 4] Biogen Inc. Insider Trading Activity

BIIB Stock Data

19.19B
146.22M
0.21%
94.46%
2.54%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
United States
CAMBRIDGE